Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 3, 2008, Pages 1079-1084

  Schmid, Cullen L ^a   Raehal, Kirsten M ^a   Bohn, Laura M ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

5 HT2A receptor; G protein coupled receptor; Internalization; MAP kinase; Schizophrenia

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; BETA ARRESTIN 2; SEROTONIN; SEROTONIN 2A RECEPTOR; BETA ARRESTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RETINA S ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; HEAD TWITCH; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; DRUG EFFECT; DRUG POTENTIATION; GENETICS; METABOLISM; MOUSE MUTANT; PHOSPHORYLATION; PROTEIN BINDING;

MUS;

ANIMALS; ARRESTINS; CELL LINE; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, SEROTONIN, 5-HT2A; SIGNAL TRANSDUCTION;

EID: 38949210817     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0708862105     Document Type: Article

References (37)

1. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) J Pharmacol Exp Ther 320:1-13.
2. Violin JD, Lefkowitz RJ (2007) Trends Pharmacol Sci 28:416-422.
3. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT (1999) Science 286:2495-2498.
4. Bohn LM, Gainetdinov RR, Caron MG (2004) Neuromol Med 5:41-50.
5. Raehal KM, Walker JK, Bohn LM (2005) J Pharmacol Exp Ther 314:1195-1201.
6. Wang Q, Zhao J, Brady AE, Feng J, Allen PB, Lefkowitz RJ, Greengard P, Limbird LE (2004) Science 304:1940-1944.
7. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005) Cell 122:261-273.
8. Gainetdinov RR, Bohn LM, Sotnikova TD, Cyr M, Laakso A, Macrae AD, Torres GE, Kim KM, Lefkowitz RJ, Caron MG, et al. (2003) Neuron 38:291-303.
9. Bohn LM, Lefkowitz RJ, Caron MG (2002) J Neurosci 22:10494-10500.
10. Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, et al. (2007) Neuron 53:439-452.
11. Nichols DE (2004) Pharmacol Ther 101:131-181.
12. McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE (2006) J Med Chem 49:5794-5803.
13. Bhatnagar A, Sheffler DJ, Kroeze WK, Compton-Toth B, Roth BL (2004) J Biol Chem 279:34614-34623.
14. Gray JA, Roth BL (2001) Brain Res Bull 56:441-451.
15. Kurrasch-Orbaugh DM, Parrish JC, Watts VJ, Nichols DE (2003) J Neurochem 86:980-991.
16. Corne SJ, Pickering RW (1967) Psychopharmacologia 11:65-78.
17. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG (2004) Annu Rev Neurosci 27:107-144.
18. Gelber EI, Kroeze WK, Willins DL, Gray JA, Sinar CA, Hyde EG, Gurevich V, Benovic J, Roth BL (1999) J Neurochem 72:2206-2214.
19. Gray JA, Sheffler DJ, Bhatnagar A, Woods JA, Hufeisen SJ, Benovic JL, Roth BL (2001) Mol Pharmacol 60:1020-1030.
20. Fiorica-Howells E, Hen R, Gingrich J, Li Z, Gershon MD (2002) Am J Physiol Gastrointest Liver Physiol 282:G877-G893.
21. Hedlund PB, Danielson PE, Thomas EA, Slanina K, Carson MJ, Sutcliffe JG (2003) Proc Natl Acad Sci USA 100:1375-1380.
22. Glennon RA (1986) Life Sci 39:825-830.
23. Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VL, Schmidt CJ (1993) J Pharmacol Exp Ther 266:684-691.
24. Pierce KL, Lefkowitz RJ (2001) Nat Rev Neurosci 2:727-733.
25. Xia Z, Hufeisen SJ, Gray JA, Roth BL (2003) Neuroscience 122:907-920.
26. Kohout TA, Lin FS, Perry SJ, Conner DA, Lefkowitz RJ (2001) Proc Natl Acad Sci USA 98:1601-1606.
27. Gray JA, Bhatnagar A, Gurevich VV, Roth BL (2003) Mol Pharmacol 63:961-972.
28. Berry SA, Shah MC, Khan N, Roth BL (1996) Mol Pharmacol 50:306-313.
29. Willins DL, Berry SA, Alsayegh L, Backstrom JR, Sanders-Bush E, Friedman L, Roth BL (1999) Neuroscience 91:599-606.
30. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, Lefkowitz RJ (2001) Proc Natl Acad Sci USA 98:2449-2454.
31. Meltzer HY (2002) in Neuropsychopharmacology: The Fifth Generation of Progress, eds Davis KL, Charney D, Coyle JT, Nemeroff C (Raven, New York), pp 819-832.
32. Willins DL, Alsayegh L, Berry SA, Backstrom JR, Sanders-Bush E, Friedman L, Khan N, Roth BL (1998) Ann NY Acad Sci 861:121-127.
33. Gainetdinov RR, Bohn LM, Walker JK, Laporte SA, Macrae AD, Caron MG, Lefkowitz RJ, Premont RT (1999) Neuron 24:1029-1036.
34. Askwith CC, Wemmie JA, Price MP, Rokhlina T, Welsh MJ (2004) J Biol Chem 279:18296-18305.
35. Mu Y, Otsuka T, Horton AC, Scott DB, Ehlers MD (2003) Neuron 40:581-594.
36. Bohn LM, Dykstra LA, Lefkowitz RJ, Caron MG, Barak LS (2004) Mol Pharmacol 66:106-112.
37. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, Bohn LM (2007) Mol Pharmacol 71:549-557.